Dermato-neuro Syndrome after COVID-19 Vaccination in a Patient with Scleromyxoedema Previously Controlled with Bortezomib and Intravenous Immunoglobulins

Gallo, Rosella; Trave, Ilaria; Cotzia, Emilia; Russo, Roberto; Parodi, Aurora

doi:10.2340/actadv.v102.4430

Cited by 3 publications

(1 citation statement)

References 16 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…IgG levels in the cerebral microvasculature may rise as a result of increased blood–brain barrier permeability caused by increased IL‐6 production, which could result in neurologic symptoms. IL‐6 has been demonstrated to control blood–brain barrier permeability, 10 but a highly inflammatory state triggered by a recent viral infection or vaccination may increase the risk of developing it 11 . Low‐dose glucocorticoids may reduce the risk of DNS in patients with SMX by suppressing inflammatory responses.…”

Section: Discussionmentioning

confidence: 99%

Dermato‐neuro syndrome after COVID‐19 infection in a patient with scleromyxoedema: Previously successful treatment with intravenous immunoglobulins

Li,

Wang,

Wang

et al. 2023

The Journal of Dermatology

View full text Add to dashboard Cite

Scleromyxedema (SMX) is a rare disease of unknown cause. It is a chronic, progressive, metabolic disorder characterized by a generalized papular and scleroderma‐like rash, as well as a subtype of lichen myxedematosus. Dermato‐neuro syndrome (DNS) is a rare neurological complication of SMX. It has flu‐like prodromal symptoms; consists of a triad of fever, coma, and seizures; and can be life‐threatening. We describe a patient with SMX complicated by DNS after infection with COVID‐19. Her symptoms resolved after treatment with acyclovir and low‐dose glucocorticoids, suggesting that DNS seizures may have a viral cause. Her skin lesions also improved after seven courses of intravenous immunoglobulin treatment, confirming that intravenous immunoglobulin is effective in these cases.

show abstract

Section: Discussionmentioning

confidence: 99%

Dermato‐neuro syndrome after COVID‐19 infection in a patient with scleromyxoedema: Previously successful treatment with intravenous immunoglobulins

Li,

Wang,

Wang

et al. 2023

The Journal of Dermatology

View full text Add to dashboard Cite

show abstract

Immune globulin/tozinameran

2023

Reactions Weekly

View full text Add to dashboard Cite

Widespread livedo racemosa

Zhao

Luu²,

Gish

et al. 2023

Clinical and Experimental Dermatology

View full text Add to dashboard Cite

Scleromyxedema is a primary cutaneous mucinosis often associated with paraproteinemias, such as MGUS. Scleromyxedema typically presents with firm, waxy papules on the hands, head, trunk, or thighs. Livedo racemosa is a rare manifestation that may only be present in a minority of cases. There are no consensus guidelines on the treatment of scleromyxedema. However, the most commonly used first-line treatment is high-dose IVIG.

show abstract

Dermato-neuro Syndrome after COVID-19 Vaccination in a Patient with Scleromyxoedema Previously Controlled with Bortezomib and Intravenous Immunoglobulins

Abstract: is missing (Short communication)

Cited by 3 publications

References 16 publications

Dermato‐neuro syndrome after COVID‐19 infection in a patient with scleromyxoedema: Previously successful treatment with intravenous immunoglobulins

Dermato‐neuro syndrome after COVID‐19 infection in a patient with scleromyxoedema: Previously successful treatment with intravenous immunoglobulins

Immune globulin/tozinameran

Widespread livedo racemosa

Contact Info

Product

Resources

About